小剂量干扰素与胸腺肽联合对慢性乙型肝炎抗病毒效应的追踪观察

Followed-up Observation on Antiviral Effect of Combined Treatment of Small Dosage of Interferon and Thymosin in Patients with Chronic Hepatitis B

本文报道小剂量干扰素与胸腺肽联合对慢性乙肝20例抗病毒效应的追踪观察结果,并与同期同批同剂量单纯干扰素治疗13例慢性乙肝作对照,追踪时间均为治后半年—2年,从HBeAg、HBcAg、DNAP、HBV DNA阴转率来看,治疗组分别为58.8％、60％、60％及66.6％、对照组分别为50％、50％、100％及50％。再从HBV四项复制指标改变来看,则治疗组4例全阴转,7例仅一项阳性,总有效率达61.1％(11/18),而对照组仅为20％(2/10),P<0.01,认为干扰素与胸腺肽联合治疗优于对照组,并扼要讨论增强干扰素抗病毒效应的各种措施,认为干扰素与胸腺肽联合,不论从前已报道近期疗效和本文远期追踪来看均较安全而有效,二者合用起到增强抗病毒效应的作用,值得进一步探索。

In this paper, followed-up observation during half to 2 years was taken in 20 cases with chronic hepatitis B who had been treated by combining small dosage of interferon with thymosin. Another 13 cases of chronic hepatitis B were treated only with interferon in the same dosage and period. The results showed that the negative percentage of HBeAg, HBeAg, DNAP, HBV-DNA were 58.8％, 60％, 60％ and 66.6％ respectively in the treated group. In the contrast group, the negative percentage of the same marks was 50％, 50％, 100％ and 50％ respectively. Then the observation was taken from HBV four replicated markers, 4 cases fully returned into negative, 7 cases had only one positive marker, thus the total effect rate was 61.1％ (11/18) in the treated group. But the same rate in the contrast group was only 20％ (2/10). The effect rate between the two groups was remarkable distinctive (p<0.01), The antiviral effect of combined treatment was prominent to the contrast group. The varied methods which were used to strengthen the antiviral effect of interferon have been discussed. The results of the recent and followed-up period showed that the combined treatment of small dosage of interferon and thymosin were safe and effective. The combined treatment plays the role to strengthen the antiviral effect that must be further studied.